Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP513912.RAncrV8n3WGiQ9iRxwHwX_nF2e7DMSlQu40lY9-oAqitI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP513912.RAncrV8n3WGiQ9iRxwHwX_nF2e7DMSlQu40lY9-oAqitI130_assertion type Assertion NP513912.RAncrV8n3WGiQ9iRxwHwX_nF2e7DMSlQu40lY9-oAqitI130_head.
- NP513912.RAncrV8n3WGiQ9iRxwHwX_nF2e7DMSlQu40lY9-oAqitI130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP513912.RAncrV8n3WGiQ9iRxwHwX_nF2e7DMSlQu40lY9-oAqitI130_provenance.
- NP513912.RAncrV8n3WGiQ9iRxwHwX_nF2e7DMSlQu40lY9-oAqitI130_assertion evidence source_evidence_literature NP513912.RAncrV8n3WGiQ9iRxwHwX_nF2e7DMSlQu40lY9-oAqitI130_provenance.
- NP513912.RAncrV8n3WGiQ9iRxwHwX_nF2e7DMSlQu40lY9-oAqitI130_assertion SIO_000772 21641642 NP513912.RAncrV8n3WGiQ9iRxwHwX_nF2e7DMSlQu40lY9-oAqitI130_provenance.
- NP513912.RAncrV8n3WGiQ9iRxwHwX_nF2e7DMSlQu40lY9-oAqitI130_assertion wasDerivedFrom befree-20140225 NP513912.RAncrV8n3WGiQ9iRxwHwX_nF2e7DMSlQu40lY9-oAqitI130_provenance.
- NP513912.RAncrV8n3WGiQ9iRxwHwX_nF2e7DMSlQu40lY9-oAqitI130_assertion wasGeneratedBy ECO_0000203 NP513912.RAncrV8n3WGiQ9iRxwHwX_nF2e7DMSlQu40lY9-oAqitI130_provenance.